CHCHD2 harboring Parkinson's disease-linked T61I mutation precipitates inside mitochondria and induces precipitation...

Area of Science:

• Mitochondrial biology
• Neurodegenerative diseases
• Protein biochemistry

Background:

• Autosomal dominant Parkinson's disease (PD) is linked to mutations in the CHCHD2 gene.
• The exact mechanisms by which CHCHD2 mutations cause PD remain unclear.
• CHCHD2 is a protein located in the mitochondrial intermembrane space.

Purpose of the Study:

• To investigate the subcellular localization and solubility of wild-type (WT) and T61I mutant CHCHD2.
• To elucidate the pathogenic mechanisms underlying T61I-induced PD.
• To understand the dominant-negative effect of mutant CHCHD2 on WT CHCHD2.

Main Methods:

• Comparison of subcellular localization and solubility of WT and T61I CHCHD2 in human cells.
• Analysis of mitochondrial targeting sequences and cysteine residues.
• Assessment of reactive oxygen species production and apoptosis.
• Evaluation of the effect of cytosolic retention on mutant CHCHD2.

Main Results:

• Mitochondrial targeting of CHCHD2 depends on C-terminal cysteine residues, not the N-terminal sequence.
• The T61I mutation causes CHCHD2 precipitation in the mitochondrial intermembrane space.
• T61I CHCHD2 increases mitochondrial reactive oxygen species and apoptosis, effects preventable by antioxidants.
• Mutating cysteine residues to retain T61I CHCHD2 in the cytosol prevents precipitation and apoptosis.
• T61I CHCHD2 significantly reduces the solubility of WT CHCHD2.

Conclusions:

• The T61I mutation leads to insoluble, likely non-functional CHCHD2 within mitochondria.
• Mutant CHCHD2 exhibits a dominant-negative effect on WT CHCHD2 solubility, explaining dominant PD inheritance.
• Targeting mitochondrial solubility could be a therapeutic strategy for this form of Parkinson's disease.